(Q39340968)

English

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model

scientific article published on 28 May 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

lymphangiogenesis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Xiping Xin

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mousumi Majumder

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Gannareddy V Girish

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Vik Mohindra

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Takayuki Maruyama

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Peeyush K Lala

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Laboratory Investigation

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1115-1128

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The role of cyclooxygenases in inflammation, cancer, and development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Cyclooxygenases, prostanoids, and tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Lymphangiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Lack of lymphangiogenesis during breast carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Coxibs and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Prostanoid receptors: subtypes and signaling

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Prostaglandin E receptors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

21 January 2018

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.90

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LABINVEST.2012.90

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39340968&oldid=2202793034"